Barclays Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $160

Benzinga · 2d ago
Barclays analyst Emily Field maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and raises the price target from $145 to $160.